Advance Biopharma ESG Reporting Strategy, Accelerate Towards Net Zero & Transform Social Impact to Prepare for Regulatory Disclosures & Become a More Sustainable Business
Boston, MA | October 9, 10, 11
Welcome to the ESG in Life Sciences Summit
2024 is undoubtedly a pivotal year for ESG and the larger sustainability landscape with the life sciences industry no exception to this. Biopharma companies at all stages of their sustainability journey must take drastic action to get ahead of brand-new regulations and transform their environmental sustainability and corporate social responsibility to secure their future as (compliant and) truly sustainable businesses.
Join us this October at the 3rd Annual ESG in Life Sciences Summit and uncover how to effectively execute your sustainable business strategy to satisfy future employees, customers, and investors as you balance profitability with environmental, ethical, and legal responsibility.
Why Take Part?
This unique and much-needed event is your only opportunity to understand how life sciences organizations of all sizes, and in all stages of their ESG journey in the US are overcoming industry-specific ESG challenges in 2024 and beyond.
Network with 100+ life sciences ESG, Sustainability, EHS, Investor Relations, CSR, Supply Chain, and other ESG-focused leaders from life sciences organizations and uncover the toolkit required to refine an overarching ESG and sustainable business strategy and effectively communicate its value for the business.
Leave with the best practices and innovative new approaches to enhance your ESG strategy, advance your decarbonization and other sustainability practices, and find efficient ways to comply with new regulations on time to become a more sustainable and socially conscious business.
Your 2024 Program Highlights Include:
Attend the ESG in Life Sciences Summit and uncover 22+ case studies of how life sciences organizations in the US are making strides in E, S and G including how:
Regeneron are advancing their global ESG agenda while ensuring they have regulatory readiness
Novo Nordisk has transformed their social impact and subsequently how it has improved not just the health of specific populations but company culture too
Takeda is advancing a global nature strategy including biodiversity
Gilead is building a leading culture of sustainability in pharmaceutical organizations and advanced digital transformation in ESG
Merck is tackling Scope 3 and Supplier Engagement
Smith + Nephew created a robust governance framework and is aligning with both UK and USA governance
Novartis is taking a systematic approach to embedding social impact throughout the business
Jazz Pharmaceuticals is building dynamic ESG governance at speed to address an evolving regulatory landscape and meet stakeholder needs